Medicine and Dentistry
Acute Myeloid Leukemia
45%
Adverse Event
9%
Amphotericin
9%
Amphotericin B
9%
Analysis
9%
Antibiotic Therapy
9%
Antifungal Agent
9%
Antifungal Therapy
9%
Aspiration
9%
Bone Marrow
45%
Bone Marrow Examination
9%
Broad-Spectrum Antibiotic
9%
Case Report
18%
Caspofungin
18%
Chemotherapy
18%
Chromosome
9%
Chromosome Analysis
9%
Chronic Myelogenous Leukemia
9%
Combination Therapy
9%
Cytarabine
36%
Drug Megadose
36%
Evaluation Study
9%
Fine-Needle Aspiration
9%
Fludarabine
9%
Fluorescence in Situ Hybridization
9%
Gyrase Inhibitor
9%
Hydroxyurea
9%
Idarubicin
9%
Imatinib
63%
Inpatient
18%
Interphase
9%
Leukocyte Transfusion
9%
Lung Biopsy
9%
Male
9%
Metaphase
9%
Mitoxantrone
9%
Mucormycosis
9%
Nilotinib
72%
Observation
9%
Outpatient
9%
P21
27%
Pancytopenia
18%
Patient
90%
Philadelphia 1 Chromosome
18%
Phosphotransferase Inhibitor
9%
Real Time Polymerase Chain Reaction
9%
Spontaneous Remission
9%
Therapeutic Procedure
81%
Treatment Response
9%
Tyrosine-Kinase Inhibitor
9%
Vatalanib
27%
Vorinostat
9%
INIS
antibiotics
18%
bids
9%
biopsy
9%
blasts
63%
bone marrow
54%
chemotherapy
9%
doses
36%
evaluation
9%
fluorescence
9%
hydroxamic acids
9%
hydroxyurea
9%
in-situ hybridization
9%
kinases
18%
leukemia
54%
lungs
9%
males
9%
metaphase
9%
patients
100%
ph'chromosome
9%
philadelphia chromosome
18%
polymerase chain reaction
9%
refractories
9%
signals
9%
spectra
9%
therapy
9%
transfusions
9%
translocation
18%
tyrosine
9%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Myeloid Leukemia
45%
Adverse Event
9%
Amphotericin
9%
Amphotericin B
9%
Antifungal Agent
9%
Caspofungin
18%
Chronic Myeloid Leukemia
9%
Cytarabine
36%
Dysplasia
9%
Fludarabine
9%
Gyrase Inhibitor
9%
Hydroxycarbamide
9%
Idarubicin
9%
Imatinib
63%
Mitoxantrone
9%
Mucormycosis
9%
Nilotinib
72%
Pancytopenia
18%
Philadelphia 1 Chromosome
18%
Phosphotransferase Inhibitor
9%
Prognosis
9%
Protein Tyrosine Kinase Inhibitor
9%
Remission
9%
Vatalanib
27%
Vorinostat
9%